Cardiovascular disease in chronic kidney disease

The presence of kidney disease, manifested by low glomerular filtration rates (GFR) and/or large amounts of protein in the urine, is independently associated with increased rates of cardiovascular disease (CVD). The severity of kidney disease is associated with graded increases in risk for CVD and death. Chronic kidney disease (CKD) should be recognized and treatment initiated early to maximize the chances for slowing nephropathy progression and reducing proteinuria. We recommend screening for CKD in all patients with CVD, including computing an estimated GFR and evaluating for proteinuria using a spot urine albumin:creatinine ratio. Aggressive management of traditional cardiovascular risk factors should be employed in this high-risk population, specifically rigorous hypertension control (including the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blocking agents (ARB)), management of hyperglycemia, hyperlipidemia and smoking cessation. Further studies are needed to identify the unique renal failure-related (non-traditional) risk factors that contribute to accelerated atherosclerosis in this population and performance of randomized trials to assess the effects of cardiovascular interventions in individuals with CKD.

[1]  F. Dekker,et al.  Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. , 2006, Journal of the American Society of Nephrology : JASN.

[2]  J. A. Brown,et al.  Glomerular Filtration Rate , 1967 .

[3]  Harlan M Krumholz,et al.  Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. , 2004, Journal of the American Society of Nephrology : JASN.

[4]  B. Freedman,et al.  Population-Based Screening for Family History of End-Stage Renal Disease among Incident Dialysis Patients , 2005, American Journal of Nephrology.

[5]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  R. Garrick Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease , 2008 .

[7]  T. Uzu,et al.  Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes , 2007, Diabetes.

[8]  T. Hostetter,et al.  Staging of chronic kidney disease: time for a course correction. , 2008, Journal of the American Society of Nephrology : JASN.

[9]  R. Garrick Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency , 2008 .

[10]  A. Garg,et al.  Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. , 2002, Kidney international.

[11]  Charles E. McCulloch,et al.  CHRONIC KIDNEY DISEASE AND THE RISKS OF DEATH, CARDIOVASCULAR EVENTS, AND HOSPITALIZATION , 2004 .

[12]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[13]  J. Kaufman,et al.  Age affects outcomes in chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[14]  P. Whelton,et al.  The Prevalence of Nontraditional Risk Factors for Coronary Heart Disease in Patients with Chronic Kidney Disease , 2004, Annals of Internal Medicine.

[15]  G. Filler,et al.  Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.

[16]  Amy Barreras,et al.  Angiotensin Ii Receptor Blockers , 2003, Proceedings.

[17]  G. Remuzzi,et al.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial , 1998, The Lancet.

[18]  G. Bakris,et al.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.

[19]  R. Garrick Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy , 2009 .

[20]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[21]  F. Locatelli,et al.  Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency , 1996 .

[22]  M. Glickman,et al.  Blood Pressure and Survival in the Oldest Old , 2007, Journal of the American Geriatrics Society.

[23]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[24]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  H. Parving,et al.  Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus , 2007, Journal of hypertension.

[26]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[27]  H. Parving,et al.  Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. , 2005, Kidney international.

[28]  T. Berl,et al.  Kidney-heart interactions: epidemiology, pathogenesis, and treatment. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[29]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[30]  Donald R. Miller,et al.  Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. , 2008, Archives of internal medicine.

[31]  J. Griffith,et al.  The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[33]  L. Hunsicker The consequences and costs of chronic kidney disease before ESRD. , 2004, Journal of the American Society of Nephrology : JASN.

[34]  R. Foley,et al.  Longitudinal study of racial and ethnic differences in developing end-stage renal disease among aged medicare beneficiaries. , 2007, Journal of the American Society of Nephrology : JASN.

[35]  M. Pfeffer,et al.  Cardiovascular risk in chronic kidney disease. , 2004, Kidney international. Supplement.

[36]  S. Reis,et al.  Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women , 2002, Circulation.

[37]  M. Weir Microalbuminuria and cardiovascular disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[38]  Steven Shea,et al.  Risk Factors for the Progression of Coronary Artery Calcification in Asymptomatic Subjects: Results From the Multi-Ethnic Study of Atherosclerosis (MESA) , 2007, Circulation.

[39]  Deeb N Salem,et al.  Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. , 2003, Journal of the American College of Cardiology.

[40]  M. Shlipak,et al.  Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. , 2003, Journal of the American Society of Nephrology : JASN.

[41]  Keith C. Norris,et al.  Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). , 2007, Archives of internal medicine.

[42]  P. Ruggenetu Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) , 1998 .

[43]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  J. Griffith,et al.  Cardiovascular disease and subsequent kidney disease. , 2007, Archives of internal medicine.

[45]  A. Garg,et al.  Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.

[46]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[47]  Michael M Engelgau,et al.  Chronic Kidney Disease: A Public Health Problem That Needs a Public Health Action Plan , 2006, Preventing chronic disease.

[48]  B. Kestenbaum,et al.  Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. , 2006, Kidney international.

[49]  H. Trivedi,et al.  Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[50]  F. Locatelli,et al.  Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.

[51]  L. Cooper,et al.  USRDS. 2001 Annual Data Report. , 2001, Nephrology news & issues.

[52]  A. Go,et al.  The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. , 2003, Journal of the American Society of Nephrology : JASN.

[53]  W. Keane,et al.  Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. , 2004, Kidney international. Supplement.

[54]  B. Palmer Supratherapeutic Doses of Angiotensin Receptor Blockers to Decrease Proteinuria in Patients with Chronic Kidney Disease , 2007, American Journal of Nephrology.

[55]  B. Brenner,et al.  Renal risk scores: progress and prospects. , 2008, Kidney international.

[56]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[57]  G. Becker,et al.  Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[58]  Charles E. McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[59]  J. Kalus,et al.  Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[60]  T. Dubose American Society of Nephrology Presidential Address 2006: chronic kidney disease as a public health threat--new strategy for a growing problem. , 2007, Journal of the American Society of Nephrology : JASN.

[61]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[62]  D. Charytan,et al.  The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. , 2006, Kidney international.

[63]  C. Gullion,et al.  Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. , 2004, Archives of internal medicine.

[64]  J. Coresh,et al.  Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. , 2003, Kidney international.

[65]  F. Hsu,et al.  The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study , 2005, Diabetologia.

[66]  L. Kuller,et al.  Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the Cardiovascular Health Study. , 2008, Atherosclerosis.

[67]  K. Norris,et al.  Racial differences in mortality among those with CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[68]  B. Freedman,et al.  Chronic kidney disease: cause and consequence of cardiovascular disease. , 2007, Archives of internal medicine.

[69]  C. Jurkovitz,et al.  Screening for chronic kidney disease: unresolved issues. , 2003, Journal of the American Society of Nephrology : JASN.